Wound Care Endocrinology Partnership: Glycemic Control for DFU

Wound Care Endocrinology Partnership: Glycemic Control for DFU Healing

Every wound care clinician who treats diabetic foot ulcers knows that glycemic control affects healing. But knowing it and acting on it are different things. Most wound care practices document the patient's A1c, note that it is elevated, and continue treating the wound — hoping that the primary care provider is managing the diabetes. In many cases, nobody is actively optimizing glycemic control for wound healing. The endocrinologist is the specialist equipped to do this work, and the referral from wound care to endocrinology is one of the highest-impact clinical decisions a wound care practitioner can make.

The A1c-Healing Connection

The relationship between glycemic control and wound healing is not theoretical — it is physiological and well-documented.

How hyperglycemia impairs wound healing:

Impaired neutrophil function. Elevated blood glucose reduces the ability of neutrophils to phagocytize bacteria and respond to infection. Diabetic patients with poorly controlled glucose are more susceptible to wound infections, and existing infections are harder to clear.
Impaired angiogenesis. New blood vessel formation — essential for granulation tissue development and wound bed preparation — is inhibited by chronic hyperglycemia. The wound cannot build the vascular network it needs to heal.
Collagen dysfunction. Hyperglycemia promotes non-enzymatic glycation of collagen, which reduces its structural integrity and impairs the remodeling phase of wound healing. The healed wound is weaker and more prone to breakdown.
Peripheral neuropathy progression. Ongoing hyperglycemia worsens peripheral neuropathy, which eliminates protective sensation and increases the risk of recurrent ulceration. The wound you heal today will return if the neuropathy continues to progress.
Microvascular disease. Chronic hyperglycemia damages small blood vessels, reducing perfusion at the capillary level — exactly the level that matters for wound healing. This microvascular damage compounds any existing macrovascular disease (PAD).

What the A1c tells you:

A1c < 7%: Generally adequate glycemic control for wound healing. This is the target range for most diabetic patients per ADA guidelines.
A1c 7-8%: Suboptimal. Wound healing may proceed but at a reduced rate. If the wound is not progressing despite appropriate wound care, glycemic optimization should be considered.
A1c 8-10%: Significantly impairs wound healing. Endocrinology referral is strongly indicated for any diabetic wound patient in this range.
A1c > 10%: Wound healing is severely compromised. The wound care clinician is fighting physiology. Endocrinology referral is urgent.

Critical point: A1c reflects 90-day average glucose. A patient with an A1c of 9% who was recently started on insulin may be trending down — but the wound has been healing under 90 days of poor glycemic conditions. Conversely, a patient with a "normal" A1c of 6.8% who has wide glycemic variability (frequent highs and lows) may still have impaired healing due to glucose spikes. A1c is the screening tool, not the complete picture.

When to Refer to Endocrinology

Not every diabetic wound patient needs an endocrinology referral. Primary care manages diabetes for the majority of patients. The wound care clinician should refer to endocrinology when glycemic management exceeds what primary care is achieving — or when the wound demands faster glycemic optimization than primary care timelines allow.

Referral criteria:

A1c > 8% with an active wound that is not progressing despite appropriate wound care (4-week reassessment showing < 50% area reduction).
A1c > 10% regardless of wound trajectory. At this level, glycemic control is the rate-limiting factor for healing.
Recurrent DFUs in a patient whose diabetes management has not been optimized. If the patient is on their second or third DFU and is still seeing only primary care for diabetes, endocrinology can provide the intensive management needed to break the cycle.
Insulin initiation or intensification needed but the primary care provider is not comfortable managing complex insulin regimens. Many primary care providers manage oral diabetes medications well but defer to endocrinology for basal-bolus insulin regimens, insulin pump management, or CGM optimization.
Significant glycemic variability — patient reports frequent hypoglycemia or hyperglycemia despite medication adherence. Glycemic variability itself impairs wound healing independent of average A1c.
Pre-surgical glycemic optimization. If the wound care treatment plan includes a surgical intervention (amputation, skin graft, flap coverage), the patient needs glycemic optimization before surgery to reduce surgical complications and improve post-operative healing.

The Coordination Protocol

The wound care-endocrinology partnership works best with a structured communication protocol. This does not need to be complex — it needs to be consistent.

Initial Referral Communication

When referring a wound patient to endocrinology, include:

Current A1c (date of last lab draw)
Current diabetes medication regimen (all oral agents, injectable therapies, insulin type and dose)
Wound status summary — location, size, duration, wound type (DFU, venous, pressure injury), current treatment
Clinical concern — specifically why you are referring (wound not progressing, A1c too high for healing, recurrent ulceration)
Healing timeline pressure — if the wound has a medical necessity window (4-week reassessment rule for skin substitutes, for example), communicate this so the endocrinologist understands the urgency

Ongoing Communication

After the initial referral, maintain a communication loop:

Request updated A1c at 90-day intervals during active wound treatment. This tracks whether glycemic optimization is translating to improved lab values.
Share wound measurement data with the endocrinologist. When wound healing accelerates after glycemic improvement, this data reinforces the value of the partnership and motivates continued glycemic optimization.
Communicate wound closure to the endocrinologist. This closes the referral loop and transitions the patient from acute wound-related glycemic optimization to long-term diabetes management.

What to Ask the Endocrinologist

Wound care clinicians do not need to manage diabetes medications — that is the endocrinologist's role. But understanding what the endocrinologist is doing helps coordinate care:

Has the patient been started on or intensified insulin therapy?
Is CGM (continuous glucose monitoring) being used? If so, what does the glycemic variability look like?
Are there medication interactions to be aware of? (SGLT2 inhibitors, for example, have been associated with rare cases of necrotizing fasciitis — the endocrinologist should be aware of any active wound)
What is the target A1c for this patient, given their wound and comorbidities?

Building the Endocrinology Referral Relationship

Endocrinologists who manage complex diabetic patients need wound care partners — but many do not have established referral relationships with wound care specialists. The referral traditionally flows from primary care to both specialties independently, with limited coordination between wound care and endocrinology.

Approach strategy:

Identify endocrinology practices near your service area. Focus on practices with high diabetic patient volumes — particularly those near diabetes education centers, dialysis centers, and communities with high diabetes prevalence.
Offer the clinical case. Present the data: A1c impact on wound healing, the 4-week reassessment rule, and how glycemic optimization during active wound treatment can change the healing trajectory. Endocrinologists understand the pathophysiology — they may not have considered the wound care treatment window specifically.
Make the referral bidirectional. When the endocrinologist identifies a diabetic patient with a foot wound — or a patient at high risk for DFU (neuropathy, deformity, prior ulcer history) — they refer to you. You refer glycemically uncontrolled wound patients to them. Both specialties benefit.
Share outcomes. When a wound heals in a co-managed patient whose A1c dropped from 9.5% to 7.2% during treatment, that outcome data is the foundation of the partnership. It demonstrates that glycemic optimization contributed to wound closure — which is exactly the evidence-based practice both specialties value.

For the complete DFU clinical pathway, see the Diabetic Foot Ulcer Guide.

Key Takeaways

HbA1c >8% significantly impairs wound healing -- coordinate with endocrinology to optimize glycemic control as part of the wound treatment plan
Document glycemic status and endocrinology referral at every DFU visit to support medical necessity and demonstrate comprehensive care
Build the partnership by offering wound status updates after each visit and sharing healing trajectory data correlated with A1c trends
Endocrinologists see the patients most likely to develop DFUs -- position wound care as a natural extension of their diabetes management program